MacroGenics, Inc. (MGNX) vs Entrada Therapeutics, Inc. (TRDA)
MacroGenics, Inc. and Entrada Therapeutics, Inc. are both Biotechnology companies. MacroGenics, Inc. and Entrada Therapeutics, Inc. are of similar size ($242.2M and $242.1M). MacroGenics, Inc. grew revenue faster over the last twelve months: 21.9% against −94.1%. MacroGenics, Inc. has the higher net margin (−7.97% vs −3,537.7%) and the higher return on invested capital (0.00% vs −1,060.2%). Across the 16 metrics below, MacroGenics, Inc. leads on 12 and Entrada Therapeutics, Inc. on 4.
Valuation
Profitability
| Metric | MGNX | TRDA | Biotechnology median |
|---|---|---|---|
| Gross margin | 78.07% | 100.00% | 65.16% |
| Operating margin | (18.73%) | (3,767.07%) | 0.00% |
| Net margin | (7.97%) | (3,537.73%) | 0.00% |
| Free cash flow margin | (35.80%) | (2,867.07%) | 0.00% |
| Return on equity | (32.61%) | (54.09%) | (57.72%) |
| Return on assets | (4.94%) | (44.35%) | (49.22%) |
| Return on invested capital | 0.00% | (1,060.24%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack